10-K: American Shared Hospital Services Reports Increased Revenue Driven by Retail Segment Growth in 2024

American Shared Hospital Services (ASHS) reports a 32.9% increase in total revenue for 2024, primarily driven by growth in its direct patient services (retail) segment.

Summary

• American Shared Hospital Services (ASHS) reported a 32.9% increase in total revenue for the year ended December 31, 2024, reaching $28.34 million compared to $21.325 million in 2023.
• The increase was primarily attributed to revenue generated from the company's single-unit radiation therapy facility in Puebla, Mexico, and the three single-unit radiation therapy facilities acquired in Rhode Island.
• Revenue from the medical equipment leasing segment decreased by $1.988 million due to lower PBRT volumes and contract expirations.
• The direct patient services (retail) segment saw a significant increase of $9.003 million, driven by higher volumes at international Gamma Knife facilities and the newly acquired radiation therapy facilities.
• The company reported a net income attributable to ASHS of $2.186 million, or $0.33 per diluted share, compared to $0.610 million, or $0.10 per diluted share, in the previous year.
• The company recognized a bargain purchase gain of $3.794 million related to the Rhode Island acquisition.
• The company recognized a loss on the write-down of impaired assets of $3.084 million, primarily related to its Gamma Knife portfolio.
• The company's cash and cash equivalents decreased to $11.275 million from $13.808 million in the prior year.
• The company amended its credit agreement to include financing for capital expenditures and the Rhode Island acquisition.
• The company is addressing a material weakness in its internal control over financial reporting by hiring additional accounting and finance personnel.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. While revenue and net income have increased, there are concerns about internal controls, debt, and asset impairments. The bargain purchase gain is a positive, but the overall outlook is cautiously optimistic.

Positives

• Significant revenue growth in the direct patient services (retail) segment.
• Overall increase in net income attributable to ASHS.
• Bargain purchase gain from the Rhode Island acquisition.
• Amendment of credit agreement to secure financing for capital expenditures and acquisitions.

Negatives

• Decrease in revenue from the medical equipment leasing segment.
• Loss on the write-down of impaired assets, primarily related to the Gamma Knife portfolio.
• Identification of a material weakness in internal control over financial reporting.
• Increased interest expense due to higher borrowings.

Risks

• The company's failure to file certain financial statements in connection with the RI Acquisition pursuant to Rules 8-04 and 8-05 of Regulation S-X and Item 9.01 of Form 8-K will limit the Company's ability to raise capital.
• The company may fail to successfully integrate the interests acquired in the RI Acquisition with its legacy business in a timely manner, which could have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows, or the Company may fail to realize all of the expected benefits of the RI Acquisition, which could negatively impact the Company's future results of operations.
• The company's failure to remediate its material weakness in its internal control over financial reporting could adversely affect its ability to report its financial condition and results of operations in a timely and accurate manner, and may adversely affect investor confidence, our reputation, and our business operations and financial condition.
• The Companys cash flow could become insufficient to service its debt due to financial, business, and other factors.
• A small number of customers account for a major portion of our revenues and the loss of any one of these significant customers could have a material adverse effect on the Company's business and results of operations.

Future Outlook

The Company anticipates the facility being built and treating its first patient in approximately 36 months. The Company anticipates the facility being built and treating its first patient in approximately 18 to 24 months. The Company does not expect that Newco will begin treating patients until mid to late 2025.

Industry Context

The company is expanding its product mix to include LINACs, MR LINACs, PET LINACs and is continuing to market PBRT units, but there can be no assurance that the Company will be successful in placing these products with customers.

Comparison to Industry Standards

• The Company estimates that there are two other companies that actively provide alternative, non-conventional Gamma Knife financing to potential customers.
• The Companys relationship with Elekta, the manufacturer of the Leksell Gamma Knife unit, is non-exclusive, and the Company has lost sales to customers that chose to purchase a Gamma Knife unit directly from Elekta.
• The Company also has several competitors in the financing of proton therapy projects.
• The Company has purchased one MEVION S250.
• The Mevion system, as well as single room proton therapy systems from other manufacturers, potentially provides cancer centers the opportunity to introduce single treatment room PBRT services with a cost in the range of approximately $30 to $50 million versus four and five PBRT treatment room programs costing in excess of $120 million including facility costs.
• There are primarily three linear accelerator OEMs; Varian, Elekta and Accuray.

Management Changes

Legal Proceedings

• There are no material pending legal proceedings involving the Company or any of its property.
• The Company knows of no legal or administrative proceedings against the Company contemplated by governmental authorities.

Related Party Transactions

• The Company's Gamma Knife business is operated through its 81% indirect interest in its GKF subsidiary.
• The remaining 19% of GKF is owned by a wholly owned U.S. subsidiary of Elekta, which is the manufacturer of the Gamma Knife.
• Since the Company purchases its Gamma Knife units from Elekta, there are significant related party transactions with Elekta such as equipment purchases, commitments to purchase and service equipment, and costs to de-install and maintain the equipment.

Stakeholder Impact

• The company's performance and strategic decisions can impact shareholders, employees, customers, suppliers, and creditors.
• The company's ability to secure additional customers for stereotactic radiosurgery equipment, advanced radiation therapy equipment and services and other proton beam radiation therapy services, or other equipment, is dependent on its ability to effectively compete against the manufacturers of these systems selling directly to potential customers and other companies that outsource these services.

Next Steps

• The Company anticipates the facility being built and treating its first patient in approximately 36 months.
• The Company anticipates the facility being built and treating its first patient in approximately 18 to 24 months.
• The Company does not expect that Newco will begin treating patients until mid to late 2025.
• The Company expects to construct a linear accelerator facility on this real property.
• The Company expects to complete this upgrade during the second quarter of 2025.

Key Dates

Keywords

Gamma Knife, radiation therapy, proton beam radiation therapy, medical equipment leasing, direct patient services, RI Acquisition, revenue, profitability, financial results, ASHS